1. Prognostic value of immunohistochemical expression of HER-2/neu in patients with lung carcinoma
- Author
-
Beti Zafirova Ivanovska, Biljana Ilievska Poposka, Simonida Jovanovska Crvenkovska, Gordana Petrusevska, Tome Stefanovski, and Snezana Smickova
- Subjects
Oncology ,medicine.medical_specialty ,Lung ,business.industry ,Cell ,medicine.disease ,medicine.disease_cause ,Log-rank test ,medicine.anatomical_structure ,Internal medicine ,medicine ,Cancer research ,Carcinoma ,Immunohistochemistry ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Lung cancer ,Carcinogenesis ,business - Abstract
Background. The amplification and the overexpression of the Her-2/neu gene have been shown in certain human tumours and are postulated to be important in human carcinogenesis. In this study we evaluated the expression of HER-2/neu gene in patients with lung carcinoma (LC) and assessed its prognostic significance. Patients and methods. HER-2/neu expression was determined in 127 LC patients using immunohistochemistry (IHC) performed on paraffin-embedded section – Hercep TestTM (DAKO). Results. The overall HER-2/neu expression was seen in 36 (28.35%) of 127 LC patients. According to the histological type, HER-2/neu overexpression was detected in 12 patients with adenocarcinomas (60%), in 19 patients with squamous cell carcinomas (31.14%), in 4 patients with small cell-lung carcinomas (10%) and in 1 patient with other carcinomas (16.66%). Only in patients with small cell-lung carcinomas HER-2/ neu overexpression was in correlation with the stage of the disease (p
- Published
- 2008